Other non-PKC kinases

The term 'Other non-PKC kinases' is a collective designation used in pharmacology and biochemistry to describe a diverse set of protein kinases that are not members of the Protein Kinase C (PKC) family. This grouping is often utilized when discussing the selectivity profiles of multi-kinase inhibitors, such as midostaurin, which may have been originally developed to target PKC but were found to have significant activity against other enzymes like FLT3, KIT, and PDGFR (Source: PubMed, PMID: 12142430). These kinases include members of the receptor tyrosine kinase (RTK) family, such as VEGFR and FGFR, as well as non-receptor kinases like SYK or SRC (Source: UniProt). Because this group encompasses hundreds of distinct enzymes involved in diverse cellular processes like signal transduction, cell cycle progression, and apoptosis, targeting 'non-PKC kinases' usually implies a lack of selectivity (Source: Manning et al., Science, 2002). In clinical practice, drugs that inhibit these kinases are often used in oncology to disrupt multiple signaling pathways simultaneously, though this broad activity also increases the risk of systemic toxicity (Source: NIH). The mechanism of action typically involves competitive binding at the ATP-binding site, which is highly conserved across the human kinome (Source: PubChem).

Other names

Non-PKC protein kinasesMiscellaneous protein kinasesOff-target kinasesBroad-spectrum kinases

Competitive inhibition of the ATP-binding site across various kinase families, leading to the modulation of multiple downstream signaling pathways.